Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ibalizumab + chidamide
- Development stage
- Unknown
- Lead developer
- Zhejiang University
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Ibalizumab + chidamide is an investigational combination regimen being evaluated for the treatment of HIV-1 infection, specifically targeting the reduction of the latent HIV reservoir. This therapeutic approach utilizes a 'shock and kill' strategy: chidamide (also known as tucidinostat) acts as a selective histone deacetylase (HDAC) inhibitor and latency reversal agent to reactivate ('shock') latent HIV-1 from cellular reservoirs, while ibalizumab, a humanized IgG4 monoclonal antibody, acts as a post-attachment inhibitor by binding to domain 2 of the CD4 receptor to block viral entry and facilitate the clearance ('kill') of reactivated cells. The combination is currently being studied in a Phase 1 dose-escalation clinical trial led by the First Affiliated Hospital of Zhejiang University in adults living with HIV who are on stable antiretroviral therapy (ART).
- Other names
- ibalizumab + tucidinostat
02
Targets
HDAC11 (Histone Deacetylase 11)HDAC10 (Histone Deacetylase 10)HDAC1 (Histone Deacetylase 1)HDAC8 (Histone Deacetylase 8)CD4 (T lymphocyte surface antigen)
Beyond the preview
Go deeper on ibalizumab + chidamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ibalizumab + chidamide.